PLATFORM TECHNOLOGY TO IMPROVE CELL PERFORMANCE
Vision
At APPLIED CELL TECHNOLOGY, we were dedicated to unlocking the potential of cells and finding ways to improve their performance. Through our innovative technology, we could increase cells’ tolerance to adverse conditions, allowing them to be effectively and successfully used in various medical treatments such as assisted reproductive technologies, stem cell applications and cryopreservation. We have developed a range of protocols and products for the treatment of cells to boost their intrinsic tolerance and performance.
Our cell therapy is the preconditioning treatment for cells.
Our aim is to make cell preconditioning an accessible, general, first choice solution for various labs. We are confident that our revolutionary technology is the way forward in cell preconditioning.
TECHNOLOGY
What if we could ...
• actively train, prepare the cells (spermatozoa, oocytes, embryos, stem cells…) themselves?
​
• make cells stronger to survive in vitro procedures better; retain or even improve their function?
​
• improve cells` resistance, endurance?
The principal approach in in vitro embryo culture and manipulation has been a defensive one: procedures aim to satisfy passively the supposed or real physiological needs of gametes and embryos. Similarly, during cryopreservation the aim is to cause minimal damage to cells whilst attempting to obtain the highest achievable cell survival.
However, carefully chosen and precisely controlled mild stress treatment of cells - cell preconditioning by hydrostatic pressure - has been described to improve embryos', gametes' and other cells` performance, and, as a consequence, subsequent survival, fertilization, continued in vitro development, pregnancy and farrowing/birth rates improved considerably compared with untreated controls.
This strategy opens up a new approach: instead of - and besides - trying to passively reduce the harm to cells during in vitro manipulations and culture, preconditioning procedures also prepare the cells themselves to ward off or reduce the damage by tuning up the cells' own, inner capacities, defense mechanisms.
Intellectual Property
The technology and the devices have been invented and developed by the team of Applied Cell Technology ltd. The first two patent families were submitted in 2003 and 2004, have been granted and validated in most part of the world, including EU, USA, Australia, China, Japan, Brazil. Some of these patents are still valid, some are lapsed however these patent families strongly bond the technology to Applied Cell Technology Inc. and provide an evident Freedom to Operate worldwide.
Research work performed in 2020 - 2023 has brought novelties regarding improved protocols. The IP for novel protocols is being finalized and submitted in Q3, 2023.
Applied Cell Technology ltd. has developed a series of devices to safely and precisely execute the preconditioning protocol. HHP 100 is capable of generating hydrostatic pressure up to 900 bars in any profile, and has a 100 cc capacity. This device is used to treat embryos, oocytes, sperm (human), embryoid bodies and other cell types with minimal volume.
HHP 1500 generates controlled hydrostatic pressures up to 400 bars and is used to treat samples with larger volumes such as human umbilical chord blood, cell suspensions, horse, boar or bull semen of many individuals.
These devices have been sold for research partners and independent institutes world-wide and were used to generate data for dozens of research papers, abstracts and presentations. See Publications tab.
Currently a new, automated device is being designed to serve the needs of human labs.
About us
The concept of cell preconditioning has stemmed from a university PhD program. The project has continued in a start-up company in 2005, that has won numerous national and international research grants. The company, called Cryo-Innovation Ltd. at that time, has built up a wide network of research cooperations and has conducted collaborative research with prestigious institutes and universities world-wide. With several rounds of VC funding the company could also develop automated devices to create and execute treatment protocols. With new investments the company continued as Applied Cell Technology Inc. that has now finished the research phase and is ready to take the next leap.
